FDA WARNING_LETTER - Stanmore Implants Worldwide Ltd. - July 31, 2014

On November 26, 2014, the FDA issued a Warning Letter to Stanmore Implants Worldwide Ltd. following an inspection from July 28-31, 2014. The inspection revealed that the firm's implantable extendable femoral and total knee replacement devices were adulterated under 21 U.S.C. § 351(h) due to non-conformity with Quality System (QS) regulation 21 CFR Part 820.

Key violations included: 1. **Failure to establish and maintain CAPA procedures (21 CFR 820.100):** The CAPA procedure was deficient, lacking requirements for statistical methodology, dissemination of quality problem information, and documentation of all CAPA activities. Furthermore, CAPAs were closed without complete implementation or verification of effectiveness. The firm's response was inadequate, failing to address retrospective review of closed CAPAs or personnel training. 2. **Failure to establish and maintain complaint handling procedures (21 CFR 820.198):** The complaint procedure was deficient, lacking requirements for uniform and timely processing, documentation of oral complaints, MDR reportability evaluation, and comprehensive investigation records. The firm's response was inadequate, not addressing personnel training or retrospective complaint review. 3. **Failure to establish and maintain Design History Files (DHFs) (21 CFR 820.30(j